ONO-4538: Phase I started

Innate Pharma S.A. (Euronext:IPH, Marseille, France) said Bristol-Myers began an open-label, U.S. Phase I trial to evaluate 0.1-3 mg/kg doses of BMS-986015 in combination with 3 mg/kg BMS-936558 in about 150 patients with advanced solid tumors. Under an expanded deal, Bristol-Myers has worldwide rights to BMS-936558 from Ono, excluding Japan, Korea and Taiwan, where Ono retains rights. Bristol-Myers gained North America rights to the product through its 2009 acquisition of Medarex Inc., which originally partnered with Ono in 2005 (see BioCentury, May 16, 2005; Sept. 7, 2009; & Sept. 26, 2011). ...